| metastatic-recurrent HNSCC (mHNSCC) | |||
| mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | mHNSCC - L2 - PDL1 positive | |
| immune chekpoint inhibitors | |||
| anti-PD-(L)1 | |||
| durvalumab based treatment | |||
| durvalumab alone | EAGLE ... | ||
| nivolumab based treatment | |||
| nivolumab alone | CheckMate 141 | ||
| pembrolizumab based treatment | |||
| pembrolizumab alone | KEYNOTE-040 ... | KEYNOTE-040 ... | |
| Immune checkpoint association | |||
| durvalumab plus tremelimumab | EAGLE ... | CONDOR ... CONDOR ... | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
